Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients-Reference-Cited by-同舟云学术

Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients

Published:2019-08 Issue:8 Volume:9 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Silzle Tobias,Blum Sabine,Schuler Esther,Kaivers Jennifer,Rudelius Martina,Hildebrandt Barbara,Gattermann Norbert,Haas Rainer,Germing Ulrich

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-019-0223-7.pdf

Reference31 articles.

1. Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079–2088 (1997).

2. Greenberg, P. L. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454–2465, https://doi.org/10.1182/blood-2012-03-420489 (2012).

3. Lee, E.-J., Podoltsev, N., Gore, S. D. & Zeidan, A. M. The evolving field of prognostication and risk stratification in MDS. Recent developments and future directions. Blood Rev. 30, 1–10, https://doi.org/10.1016/j.blre.2015.06.004 (2016).

4. Ray-Coquard, I. et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 69, 5383–5391, https://doi.org/10.1158/0008-5472.CAN-08-3845 (2009).

5. Germing, U. et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91, 1596–1604 (2006).

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDS patient registries - achievements and challenges;Annals of Hematology;2024-08-23

2. Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes;British Journal of Haematology;2024-07-31

3. Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium;HemaSphere;2024-05

4. Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M;Blood Cancer Journal;2023-12-21

5. A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count;American Journal of Hematology;2023-09-04